dromlakhani Perform imaging after biochemical diagnosis of acromegaly
STEP 1 — Gather Information
Collect confirmed biochemical diagnosis: serum IGF-1 above age‑adjusted normal range and GH nadir ≥0.4 µg/L after 75g oral glucose tolerance test. Document any clinical features (e.g., acral enlargement, headaches) and screen for MRI contraindications (pacemaker, claustrophobia, ferromagnetic implants).
STEP 2 — Rule In / Rule Out
If IGF-1 is elevated and GH nonsuppressed (≥0.4 µg/L post‑OGTT), rule in acromegaly and proceed to imaging; otherwise rule out acromegaly and consider alternative diagnoses (do not order pituitary imaging for acromegaly work‑up).
STEP 3 — Classify or Stratify
Assess MRI suitability: if no contraindications, select MRI as the modality of choice; if MRI is contraindicated or unavailable, classify for CT scan. This decision determines the imaging protocol to be used.
STEP 4 — Decide
Order a pituitary MRI with 2‑mm slices (or CT scan if MRI contraindicated) to visualize tumor size, appearance, and parasellar extent prior to surgical planning.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on CT when MRI is available; do not skip imaging before surgery; avoid mistaking an empty sella for a normal pituitary; recognize that routine MRI may miss microadenomas—use thin‑cut slices; never use imaging to establish the biochemical diagnosis; do not proceed to imaging if IGF‑1 and GH suppression tests are not diagnostic.
Concrete Clinical Example
A 48‑year‑old presents with shoe‑size enlargement and frontal bossing. IGF‑1 is 820 ng/mL (elevated) and GH is 1.8 µg/L after OGTT (nonsuppressed). Biochemical diagnosis confirmed. No MRI contraindications. A pituitary MRI with 2‑mm slices reveals a 14‑mm macroadenoma with right cavernous sinus invasion.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2700